Referred to us by their bankers, Sonoma sought a fresh narrative that could resonate with investors without getting lost in scientific jargon.  

Leveraging our expertise in science communication, marketing, and design, we reimagined their broad “balancing the immune system” narrative. Instead, we crafted a compelling message, tailored to their differentiated scientific approach: “Chronic diseases don’t have to be treated chronically.” This shift not only highlighted Sonoma’s unique positioning but also differentiated them in a competitive field. 

We developed a sophisticated design style to reflect Sonoma’s prestigious standing in the field of immunology. We simplified complex scientific concepts into an accessible, persuasive narrative tailored for investors, and created a new corporate presentation. 

The new deck was well-received at key investor conferences. It effectively showcased Sonoma’s novel approach to the treatment of autoimmune diseases through Treg cell therapies.